Hodgkin Lymphoma Treatment Market
Global Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report, by Type (Radiation therapy, Immunotherapy, Chemotherapy, and Others), and Forecast Period, 2020-2026. Update Available - Forecast 2024-2030
The global Hodgkin lymphoma treatment market is estimated to grow at a CAGR of around 8% during the forecast period (2020-2016). A Hodgkin lymphoma includes symptoms such as swelling in lymph nodes that causes tumor below the skin. This disease was widely spread in the late ’20s and ’30s, which is high common in the younger population aged in-between 15 to 19. Lymphocytes are white blood cells which is a major part of immune cells. However, impaired lymphocytes multiply the lumps and increase the risk of tumors. Furthermore, a fall in the number of lymphocytes in the body decreases the capability to fight and prevent infection. Hence, to treat these diseases, there are significant demand for Hodgkin lymphoma drugs in the market.
Due to the rise in demand for lymphoma treatment and intensive Research & Development (R&D) increases the Hodgkin lymphoma treatment market growth. Apart from this, an increase in the number of investments in R&D and regulatory approval by the Food and Drug Administration (FDA) plays a significant role in market growth. The growing demand for a high energy beam to kill the cancer cells is also expected to fuel the demand for radiation therapy for the Hodgkin lymphoma treatment. According to the American Cancer Society (ACS), the rise in Hodgkin lymphoma diagnosis in the US and increases awareness among the population is also creating enormous opportunities for market growth. However, expensive lymphoma treatment and lack of awareness in emerging economies will hamper the market growth.
Segmentation
The global Hodgkin lymphoma treatment market is segmented based on type. Based on type, the market is classified into radiation therapy, immunotherapy, chemotherapy and others (stem cell transplant). The growing demand for advanced Hodgkin lymphoma treatment along with a high acceptance rate in developed nations and an increase in awareness about the Hodgkin lymphoma diagnosis is fueling the market growth during the forecast period.
Global Hodgkin Lymphoma Treatment Market Share by Type, 2019 (%)
Regional Outlook
Geographically, the global Hodgkin lymphoma treatment market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to witness significant growth in the market and is expected to retain its dominance in the coming years. According to the ACS, around 1000 death tolls in the US contributed by the age group of 15 to 19 years. Further, increases the healthcare infrastructure and advancement in technology to diagnose the lymphoma with the help of a high radiation beam is also contributing to the market share in the region. According to the Leukemia & Lymphoma Society, a rise in the number of cases of both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) is expecting to increase in demand for treatment in the US.
Global Hodgkin Lymphoma Treatment Market Growth, by Region 2020-2026
Competitive Landscape
The major companies providing Hodgkin lymphoma treatment include Bristol-Myers Squibb Co., Pfizer, Inc., Hikma Pharmaceuticals PLC, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., Fresenius Kabi USA, LLC, Genentech Inc., Leadiant Biosciences, Inc., and LGM Pharma, LLC. These players are continuously making efforts to develop advanced and efficient treatment options. For instance, in March 2018, the US FDA approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
The Report Covers
- Market value data analysis of 2020 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Hodgkin lymphoma treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Bristol-Myers Squibb Co.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Pfizer, Inc.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Hikma Pharmaceuticals PLC
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Merck & Co. Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Takeda Pharmaceutical Co. Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Hodgkin Lymphoma Treatment Market by Type
5.1.1. Radiation therapy
5.1.2. Immunotherapy
5.1.3. Chemotherapy
5.1.4. Others (Stem Cell Transplant)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Bristol-Myers Squibb Co.
7.2. Fresenius Kabi USA, LLC
7.3. Genentech Inc.
7.4. Healthgrades Operating Company, Inc.
7.5. Hikma Pharmaceuticals PLC
7.6. Leadiant Biosciences, Inc.
7.7. LGM Pharma, LLC
7.8. Merck & Co. Inc.
7.9. Mylan N.V.
7.10. NextSource Biotechnology, LLC
7.11. Pfizer, Inc.
7.12. Recordati Rare Diseases, Inc.
7.13. Seattle Genetics. Inc.
7.14. Takeda Pharmaceutical Co. Ltd.
7.15. Teva Pharmaceuticals Industries, Ltd.
1. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. GLOBAL RADIATION THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
3. GLOBAL IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
4. GLOBAL CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
5. GLOBAL OTHERS HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2015 ($ MILLION)
6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
7. NORTH AMERICAN HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
8. NORTH AMERICAN HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
9. EUROPEAN HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
10. EUROPEAN HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
11. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
12. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
13. REST OF THE WORLD HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
1. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY TYPE, 2019 VS 2026 (%)
2. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
3. US HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
4. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
5. UK HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
6. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
7. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
8. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
9. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
10. ROE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
11. INDIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
12. CHINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
13. JAPAN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
14. REST OF ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
15. REST OF THE WORLD HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2019-2026 ($ MILLION)
